Tofflon Dehui, a wholly-owned subsidiary of Tofflon Science and Technology Group Co., Ltd. (SZ: 300171), has committed to its mission “Expertise in Biopharmaceutical Industry”, specializing in pharmaceutical factory construction, R&D (research and development) and production of purifying air-conditioning equipment and pharmaceutical water equipment. We focus on high-level pharmaceutical fields, such as highly potent API and highly potent injectables, biological API and biological injectables. After serving hundreds of domestic and foreign pharmaceutical enterprises, Tofflon Dehui has accumulated a large amount of project experience and can provide clients with better service.
Tofflon Dehui was established in 2011 with registered capital of 100 million. We have a team of professional engineers, including experts familiar with GMP and GEP, and project managers with rich experience in the construction and delivery of pharmaceutical factories. Our engineers have the ability to provide a full set of technical and management service, such as BIM design, Utility equipment supplying, Clean room installation, MEP installation, factory commissioning and GMP validation. In accordance with the requirements of GB/T19001-2008/ISO9001 quality management system and ISO 14644 clean room standards, Tofflon builds pharmaceutical factories satisfying the certification requirements of China GMP, FDA and EU cGMP.
In 2018, Tofflon Dehui obtained the 3rd class qualification for general contracting on construction engineering, the 2nd class qualification for professional contracting on electronic and intelligent engineering and the 2nd class qualification for professional contracting on building decoration engineering.
In 2019, Tofflon Dehui obtained the 1st class qualification for professional contracting on MEP installation and the 2nd class qualification for professional contracting on fire fighting facilities engineering issued by the Ministry of Construction.
Tofflon Dehui has more than 300 employees, including more than 120 high and intermediate technical personnel, more than 30 constructors and associate constructors, and more than 20 GMP validation personnel.
Since its establishment, the company has been focusing on EPC general contracting, MEP installation general contracting and special contracting of core disciplines for pharmaceutical factories. Since 2012, Tofflon Dehui has completed over 100 successful cases, including the COVID-19 vaccine manufacturing base of Shanghai Shangyao CanSino Biopharmaceutical Co., Ltd. and the COVID-19 vaccine manufacturing workshop of WestVac Biopharma Co., Ltd., the COVID-19 mRNA vaccine manufacturing workshop of Guangzhou Ribobio Co., Ltd., the animal vaccine manufacturing workshop of YEBIO Bioengineering Co.,Ltd of QINGDAO, the animal vaccine manufacturing workshop of Shanghai Institute Of Biological Products Limited Liability Company., the blood product manufacturing workshop of Jiangxi Boya Bio-pharmaceutical Co., Ltd., the biological vaccine manufacturing workshop of Beijing Minhai Biotechnology Co., Ltd., the biomacromolecule manufacturing workshop of CSPC Pharmaceutical Group Co., Ltd., the lyophilized drug manufacturing workshop of Sinopharm Guorui Pharmaceutical Co., Ltd.
We always insist to meet clients’ requirements as our core among engineering design, BIM design, construction management of cleaning system, procurement, construction, installation, commissioning and validation of HVAC system, pharmaceutical water system, EMS & BMS, to provide clients with one-stop turnkey services for purification construction.